Josh Rothman practices patent and trade secret law in the pharmaceutical, biotechnology and medical device arenas. In addition to litigating complex cases in court for both the patentee and accused infringer, he counsels clients on due diligence matters in connection with mergers and acquisitions, as well as licensing and other transactional matters. He has significant experience litigating Hatch-Waxman cases, from pre-suit through appeal, involving blockbuster drugs such as Prilosec®, Accupril®, Imitrex®, Benicar® and Sensipar® including patents covering chemical compounds, polymorphs, enantiomers, salt and solvate forms, solid and sterile formulations, as well as methods of use and treatment.
In addition, Josh is also active in the firm’s pro bono practice. He has helped clients in obtaining Section 8 housing, U-visas, as well as disability benefits.
Sanofi et al. v. Glenmark Pharmaceuticals, Inc. USA et al.
Judge Andrews construed the claims of U.S. Patent No. 8,318,800 covering solid pharmaceutical formulations of the active ingredient in Multaq® in Sanofi’s favor. The Defendants stipulated to the validity of the claims of the ‘800 patent the week before trial and the parties agreed that Sanofi’s proposed construction was dispositive of the issue of infringement.